

# APOL1 variants G1, G2 and N264K affect APOL1 plasma protein concentration: a UK Biobank study

Walt E. Adamson<sup>1,2,3</sup>, Harry Noyes<sup>3,4</sup>, John Ogunsoola<sup>1,2</sup>, Rulan S. Parekh<sup>5</sup>, Anneli Cooper<sup>1,2</sup>, and Annette MacLeod<sup>1,2,3</sup>

1. School of Biodiversity, One Health, and Veterinary Medicine, University of Glasgow.
2. Wellcome Centre for Integrative Parasitology, University of Glasgow
3. TrypanoGEN+ Research Group, Member of the H3Africa Consortium
4. Centre for Genomic Research, University of Liverpool
5. Women's College Hospital, Hospital for Sick Children and University of Toronto

## Abstract

### Background

*APOL1* variants G1 and G2 are common in populations with recent sub-Saharan African ancestry. They are known to influence health conditions: most notably being associated with protection from human African trypanosomiasis and increased risk of susceptibility to chronic kidney disease. Association studies have often considered G1 and G2 as equivalent, however we recently presented evidence of substantial phenotypic differences between carriers of the two variants. An additional *APOL1* variant, N264K, has previously been shown to modify the damaging effect of G2 on the kidney. Here, we examine the influence of these variants on APOL1 protein concentration.

### Methods

Using a cohort of 1,050 UK Biobank participants with recent African ancestry, we compared APOL1 protein concentration in carriers of variants G1, G2, and N264K and performed a genome-wide association study to identify additional modifiers of APOL1 concentration. We also compared APOL1 concentration across self-reported ethnicities for all 43,330 UK Biobank participants for whom APOL1 concentration data was available.

### Findings

*APOL1* G1 and G2 are both associated with increased APOL1 protein concentration, however the effect of G2 is more marked, and it was the only locus that reached genome-wide significance in terms of association with APOL1 concentration ( $p = 3 \times 10^{-155}$ ). In a G2 background, the presence of N264K is associated with a reduction in APOL1 concentration ( $p = 6 \times 10^{-5}$ ). People with self-reported Black or Black British ethnicity have higher APOL1 concentrations all other self-reported ethnicities in the UK Biobank.

### Interpretation

These findings demonstrate the influence of *APOL1* variants and APOL1 protein concentration and identify additional phenotypic differences between the G1 and G2, highlighting the value in considering them as distinct in molecular and association studies. This work also provides further detail on the relationship between the G2 and N264K variants, which has significant implications for diagnosis and therapy in kidney disease.

## Introduction

People of recent African origin are disproportionately affected by chronic kidney disease (CKD)(1). This excess risk has been, in part, attributed to two independent variants of the apolipoprotein L1 (*APOL1*) gene known as G1 and G2(2), which are common in sub-Saharan Africa and its diaspora, but rare or absent in other populations. G1 (amino acid substitutions S342G and I384M) and G2 (deletion of N388 and Y389) are found in the same domain at the C-terminus of *APOL1*, and are in complete linkage disequilibrium with each other such that haplotypes with both G1 and G2 alleles are either very rare or absent, as a result, six combined genotypes with respect to *APOL1* G1 and G2 have been observed (Table 1).

Genotype Name	Haplotypes		Variant copy number	G1 copy number	G2 copy number
	G1 locus	G2 locus			
G0/ G0	AT AT	TTATAA TTATAA	0	0	0
G0/ G1	AT GG	TTATAA TTATAA	1	1	0
G0/ G2	AT AT	TTATAA 6 bp deletion	1	0	1
G1/ G1	GG GG	TTATAA TTATAA	2	2	0
G1/ G2	GG AT	TTATAA 6 bp deletion	2	1	1
G2/ G2	AT AT	6 bp deletion 6 bp deletion	2	0	2

**Table 1: The six observed combined genotypes with respect to the G1 and G2 loci. Genotypes with G1 and G2 on the same haplotype are theoretically possible but have not been observed.**

Heterozygosity for G1 or G2 has been shown to be associated with protection from human African trypanosomiasis (sleeping sickness)(3). The two *Trypanosoma brucei* subspecies that infect humans and cause human African trypanosomiasis, *T.b. gambiense* and *T.b. rhodesiense*, have developed specific mechanisms for avoiding lysis by *APOL1*(4). In *T.b. gambiense* infection, G1 and G2 are associated with decreased and increased risk of severe disease, respectively, while carriage of the G2 variant prevents infection by *Trypanosoma brucei rhodesiense*(3). Despite the association of different genotypes with distinct phenotypes in human African trypanosomiasis, studies of the association between kidney diseases and *APOL1* G1 and G2 have often grouped the two variants together as recessively ‘high-risk’ in any combination. Carriage of two such alleles (i.e. G1 homozygotes, G2 homozygotes, and G1/G2 compound heterozygotes) is associated with a spectrum of kidney and related conditions including focal segmental glomerulosclerosis, hypertension-associated kidney failure, and HIV-associated nephropathy(2,5–7).

Using data from the UK Biobank, we previously highlighted differences in association between the two-variant *APOL1* genotypes with kidney phenotypes, and demonstrated that one combined *APOL1* genotype, G1/G2 (carried by millions of people worldwide), is deleteriously associated with 26 different conditions spanning human health(8). Our analysis exposed complexities in the relationship between *APOL1* risk alleles and disease that are not evident when two-variant *APOL1* genotypes (G1/G1, G1/G2, and G2/G2) are grouped together as a homogeneous risk category.

*APOL1* also contains additional variants that modify its impact on the kidney and in response to trypanosome infections. One such variant, N264K, was initially identified in a G2 homozygous individual infected with an atypical *T.b. gambiense* strain that lacked the characteristic TgsGP virulence gene. Parallel *in vitro* experiments with N264K demonstrated a reduction in the lytic activity of APOL1 containing this mutation against trypanosomes *in vitro*(9). This reduced trypanolytic activity was mirrored by a reduction in cytotoxicity in HEK293 cells expression G1 and G2 variants alongside the N264K mutation(10). Subsequently, it was shown that N264K, when co-inherited with G2, also reduces the renal toxicity associated with the G1/G2 and G2/G2 genotypes(11,12).

These *APOL1* variants are incompletely penetrant and little is still known about how they drive disease. A minor fraction of APOL1 is expressed by the kidney and other tissues but the majority is produced by the liver and circulates bound in protein complexes as a component of plasma HDL. The contribution of circulating APOL1 to disease processes remains a point of investigation. Serum APOL1 levels have been correlated with some pathologies such as sepsis and COVID-19 severity(13), whereas other studies found no correlation with kidney disease risk, but genotype and ethnic variation in APOL1 levels(14). Further investigation in this area is warranted to discover the genetic drivers that influence APOL1 protein concentration.

In October 2023, the UK Biobank released plasma protein quantification data generated on the Olink platform for 3072 proteins(15,16), including APOL1. A genome-wide association study screening for associations with protein concentration in the UK Biobank identified APOL1 G2 (alongside SNPs rs138477541 or rs1053865678 on chromosomes 3 and 5 respectively) as having an association with APOL1 concentration(16). Here, we examine the impact of *APOL1* G1 and G2 variants on APOL1 protein concentration in detail and determine whether APOL1 protein concentration in a G1 or G2 background is modified by N264K.

## Methods

### Study design and participants

The UK Biobank is a prospective cohort study of 502,460 adults aged 40 to 69 years at enrolment between 2006 and 2010 from 22 assessment centres across the United Kingdom(17). At the baseline study visit, participants underwent nurse-led interviews and completed detailed questionnaires about medical history, medication use, sociodemographic factors, and lifestyle in addition to a range of physical assessments and provided blood and urine. The UK Biobank study was approved by the North-West Multi Centre Research Ethics Committee, and all participants provided written informed consent.

### Genotyping

*APOL1* genotypes were obtained from the UK Biobank, which used a custom Affymetrix array for the G1 (rs73885319) and N264K (rs73885316) alleles. G2 (rs71785313) genotypes were imputed by the UK Biobank as previously described(17). By analysing genetic principal components, we previously identified a cohort of UK Biobank participants who had recent sub-Saharan African ancestry(8). Briefly, using principal components (PC) calculated by the

UK Biobank genetic data of all UK Biobank participants, the large majority of participants with PC1 > 100 and PC2 > 0 described their ethnic background as 'Black or Black British' or 'Mixed'. We then used UK Biobank whole genome Affymetrix genotype data to calculate principal components for this cohort after removing linked SNPs. Inspection of a plot of the new PC1 and PC2 identified a core set of participants with PC1 > -0.0135, which captured 93% of the individuals in the UK Biobank with a two-risk-variant *APOL1* genotype, enabling comparison of these individuals with UK Biobank participants who were of the most similar ancestry. The data was further filtered to include only participants with complete, unambiguous *APOL1* G1 and G2 genotype data. The final cohort for analysis described here included 7,969 UK Biobank participants.

### **UK Biobank Olink protein quantification data**

Olink protein quantification was performed on 54,219 UK Biobank participants(16). *APOL1* protein quantification data is available for 43,330 of these. Olink data is expressed in the Normalized Protein eXpression (NPX) scale, enabling relative quantification of the same protein across multiple samples. As NPX values are calculated on a log2 scale, an NPX difference of 1 represents a doubling of protein concentration.

### **UK Biobank self-reported ethnicity data**

Self-reported ethnicity data was obtained from UK Biobank data field 21000. The descriptors of ethnicity used here (Asian or Asian British, Black or Black British, Chinese, Mixed, and White) represent the top level descriptors of ethnicity used in data field 21000.

### **Statistical analysis**

*APOL1* protein concentration was tested for association with *APOL1* genotypes with, age, sex, and genetic principal components 1-4 were selected as covariates. Linear regression as implemented in R was used to compare the effects of *APOL1* genotypes and individual risk alleles. All statistical tests were 2-sided, and  $p < 0.05$  was considered statistically significant.

### **Genome-wide association**

A total of 784,256 loci from the UK Biobank Affymetrix genotype data were used in a genome-wide association study for loci associated with *APOL1* concentration. We scanned for associations within our previously-defined cohort of UK Biobank participants with recent sub-Saharan African ancestry. Association testing was done using Plink2(18) with a general linear model(19), using age, sex, and the first four principal components of the relevant sample set as covariates.

## **Results**


Olink *APOL1* protein concentration data and complete *APOL1* genotypes were available for 1,050 UK Biobank participants within our previously defined cohort of participants with recent sub-Saharan African ancestry(8). Olink data is expressed in the Normalized Protein eXpression (NPX) scale, enabling relative quantification of the same protein across multiple samples. As NPX values are calculated on a log2 scale, an NPX difference of 1 represents a doubling of protein concentration. We examined whether differences in *APOL1* protein concentration were associated with the number of G1 or G2 copies present.

### **APOL1 G1 is associated with moderate increases in APOL1 protein concentration**

In the first instance, we compared the number of APOL1 G1 alleles with APOL1 protein concentration. There was no significant difference in protein levels between participants who had no G1 alleles (G0/G0, G0/G2, G2/G2) and individuals carrying one G1 allele (G0/G1 or G1/G2). Similarly, there was no significant differences in APOL1 protein levels between participants who had no G1 alleles and individuals carrying two G1 alleles (G1/G1). Likewise, there was no significant difference in APOL1 protein levels between participants who had one G1 allele and individuals carrying two G1 alleles (Table 2, Figure 1). However, when participants who carried no G1 alleles (n=637, mean APOL1 concentration = 1.06 NPX) were compared to those who were either homozygous or heterozygous for G1 (G1/G1, G0/G1 or G1/G2) (n=413, mean APOL1 concentration 1.24 NPX) a significant difference was detected (t-test, p = 0.0003).

Grouping	Number in cohort	Mean APOL1 concentration (NPX)	p (vs 0 G1 alleles)	p (vs 1 G1 allele)
0 G1 alleles (G0/G0, G0/G2, or G2/G2)	637	1.06	-	0.44
1 G1 allele (G0/G1 or G1/G2)	332	1.20	0.44	-
2 G1 alleles (G1/G1)	81	1.43	0.21	0.10
Either one or two G1 alleles (G0/G1, G1/G2, G1/G1)	413	1.24	0.0003	

**Table 2: Associations between the number of APOL1 G1 alleles carried and APOL1 plasma protein levels.** Associations were estimated using linear regression, with age, sex, and the first four principal components of the samples as covariates. NPX values are calculated on a log2 scale.




**Figure 1: Distribution of APOL1 concentrations for 0, 1, and 2 G1 alleles.** Note that some participants with 0 G1 alleles will have G2 alleles, which likely contribute to the larger variance of APOL1 NPX values for this group.

### **APOL1 G2 strongly influences APOL1 protein concentration.**

When participants were similarly grouped according to the number of G2 alleles carried, all comparisons between groupings yielded significant p-values (Table 3, Figure 2). The difference in mean NPX between participants who had 2 G2 alleles (2.88 NPX) and 0 G2 alleles (0.85 NPX) indicates a 4.1-fold difference in mean APOL1 concentration between the two groups.

Grouping	Number in cohort	Mean APOL1 concentration (NPX)	p (vs 0 G1 alleles)	p (vs 1 G1 allele)
0 G2 alleles (G0/G0, G0/G1, or G1/G1)	839	0.85	-	$< 2 \times 10^{-16}$
1 G2 allele (G0/G2 or G1/G2)	183	2.16	$< 2 \times 10^{-16}$	-
2 G2 alleles (G2/G2)	28	2.88	$< 2 \times 10^{-16}$	$1 \times 10^{-8}$
Either one or two G2 alleles (G0/G2, G1/G2, G2/G2)	211	2.26	$< 2 \times 10^{-16}$	

**Table 3: Associations between the number of APOL1 G1 alleles carried and APOL1 plasma protein levels.** Associations were estimated using linear regression, with age, sex, and the first four principal components of the samples as covariates. NPX values are calculated on a log<sub>2</sub> scale.



**Figure 2: Distribution of APOL1 concentrations for 0, 1, and 2 G2 alleles.**

### **Evidence that N264K is detected in G0 and G2 haplotypes, but not G1 haplotypes**

Our previously defined cohort(8) of UK Biobank participants with sub-Saharan African ancestry ( $n = 7,969$ ) includes 7,764 individuals with an identifiable genotype at the N264

locus. It had previously been reported that the N264K variant occurs on G0 and G2 haplotypes as a result of two independent mutational events, and that N264K is mutually exclusive with the *APOL1* G1 allele(12). UK Biobank data supports this observation: at least one haplotype containing the N264K variant was observed for 88/2,984 (2.9%) G0/G0 participants and 9/155 (5.8%) G2/G2 participants, but none of the 681 G1/G1 participants (Table 4).

Genotype	Number in cohort	0 N264K haplotypes	1 N264K haplotype	2 N264K haplotypes
G0/G0	2,984	2,896	88	0
G0/G1	2,344	2,300	44	0
G1/G1	681	681	0	0
G0/G2	1,264	1,179	85	2
G1/G2	336	317	19	0
G2/G2	155	146	9	0

**Table 4: Distribution of N264K haplotypes across *APOL1* genotypes.**

### In a G2 background, N264K reduces *APOL1* concentration

Of the 1,032 cohort members with *APOL1* protein data and complete G1, G2, and N264 genotype data, 211 carried at least one copy of G2, among whom 32 also carried the N264K variant. The presence of N264K on a G0 background (G0/G0) (t-test,  $p = 0.88$ ) or in a G1 background (genotypes G0/G1, G1/G2, or G1/G1) (t-test,  $p = 0.85$ ) had no effect on *APOL1* protein concentration. However on a G2 background (genotypes G0/G2, G1/G2, or G2/G2), the presence of N264K was associated with significantly lower *APOL1* protein level (t-test,  $p = 6 \times 10^{-5}$ ) (Table 5). The mean *APOL1* protein concentration was 28% lower among participants who carried N264K and G2 than those who carried G2 alone.

Genotype with 0 N264K alleles	Mean <i>APOL1</i> NPX, genotype 1	Genotype with $\geq 1$ N264K alleles	Mean <i>APOL1</i> NPX, genotype 2	p-value
0 G1 alleles, 0 G2 alleles	0.62	0 G1 alleles, 0 G2 alleles	0.59	0.88
$\geq 0$ G1 alleles	1.25	$\geq 0$ G1 alleles	1.20	0.85
$\geq 0$ G2 alleles	2.27	$\geq 0$ G2 alleles	1.91	$6 \times 10^{-5}$

**Table 5: The effect of the N264K genotype on backgrounds containing: 0 G1 or G2 alleles; at least one G1 allele; at least one G2 allele. NPX values are calculated on a log2 scale.**


### *APOL1* G1 and G2 combined genotypes differ in terms of *APOL1* protein concentration

Previously, phenome-wide analysis highlighted differences between the six observed combined *APOL1* G1 and G2 genotypes(8). These differences extend to protein concentration (Table 6, Figure 3). All comparisons between genotypes yielded significant p-values ( $< 8 \times 10^{-5}$ ), except for the comparison between G0/G2 and G1/G2 (Table 6). The contrast in mean *APOL1* concentration between participants who were G2/G2 (2.88 NPX) and G0/G0 (0.62 NPX) (the two most divergent genotypes) was 4.8-fold.

Genotype	Number in cohort	Mean <i>APOL1</i> concentration (NPX)	p (vs G0/G1)	p (vs G1/G1)	p (vs G0/G2)	p (vs G1/G2)	p (vs G2/G2)
G0/G0	463	0.62	$1 \times 10^{-12}$	$< 2 \times 10^{-16}$	$< 2 \times 10^{-16}$	$< 2 \times 10^{-16}$	$< 2 \times 10^{-16}$
G0/G1	295	1.05		$1 \times 10^{-6}$	$< 2 \times 10^{-16}$	$< 2 \times 10^{-16}$	$< 2 \times 10^{-16}$
G1/G1	81	1.43			$< 2 \times 10^{-16}$	$< 2 \times 10^{-16}$	$< 2 \times 10^{-16}$

G0/G2	146	2.11	0.09	$2 \times 10^{-10}$
G1/G2	37	2.35		$7 \times 10^{-5}$
G2/G2	28	2.88		

**Table 6: Associations between combinations of *APOL1* G1 and G2 genotypes and *APOL1* plasma protein levels. Associations were estimated using linear regression, with age, sex, and the first four principal components of the samples as covariates. NPX values are calculated on a log2 scale.**



**Figure 3: Distribution of *APOL1* concentrations for 0, 1, and 2 G2 alleles.**

Notably, the sub-Saharan African cohort described in this study had a mean *APOL1* normalised protein expression reading of 1.14 PX: significantly higher ( $p < 2 \times 10^{-16}$ ) than the remainder of UK Biobank participants for whom *APOL1* concentration data is available (0.06 NPX), indicating that *APOL1* protein concentration is higher on average among groups with recent sub-Saharan African ancestry. However, as described above, a proportion of this difference can be attributed to the overrepresentation of G1 and G2 alleles in this cohort, which are rare or absent in non-sub-Saharan African populations. However, among sub-Saharan African cohort members with the G0/G0 genotype, *APOL1* concentration (0.62 NPX) was also 47% higher ( $p < 2 \times 10^{-16}$ ) than the remainder of UK Biobank participants with that genotype (mean = 0.07 NPX).


To examine differences across ethnicity in further detail, we compared *APOL1* protein concentration across self-reported ethnicities as defined by the UK Biobank: White; Mixed; Asian or Asian British (which includes Indian, Pakistani, and Bangladeshi ethnicities); Black or Black British; Chinese. To eliminate the influence of *APOL1* G1 and G2, only participants who had the G0/G0 genotype were considered in this analysis. All comparisons between self-reported ethnicities yielded significant differences ( $< 3 \times 10^{-5}$ ), with the exception of the



comparison between Asian and Chinese ethnicities (Table 7, Figure 4). Consistent with the data described above, UK Biobank participants with self-reported Black or Black British ancestry had higher concentrations of APOL1 than other ethnicities.

Self-reported ethnicity	Number in group	Mean APOL1 concentration (NPX)	p (vs Black/Black British)	p (vs Chinese)	p (vs Mixed)	p (vs White)
Asian/Asian British	838	-0.15	<2x10 <sup>-16</sup>	0.31	1x10 <sup>-13</sup>	<2x10 <sup>-16</sup>
Black/Black British	446	0.60		<2x10 <sup>-16</sup>	3x10 <sup>-12</sup>	<2x10 <sup>-16</sup>
Chinese	135	-0.11			8x10 <sup>-8</sup>	2x10 <sup>-5</sup>
Mixed	240	0.22				<2x10 <sup>-16</sup>
White	41,264	0.07				

**Table 7: Mean APOL1 NPX values for individuals with the *APOL1* G0/G0 genotype by major population group (as defined by the UK Biobank). The mean of each population was significantly different from the mean of each other population, with the exception of the comparison between self-reported Asian and Chinese participants. The mean APOL1 NPX was highest in participants who identified as Black or Black British.**



**Figure 4: Distribution of APOL1 concentrations for each self-reported ethnicity (as defined by the UK Biobank).**

### Genome-wide association study to identify additional loci regulating APOL1 concentration

A previous genome-wide scan for association with APOL1 concentration reported associations in people of African ancestry between APOL1 concentration and APOL1 G2, rs138477541 (chromosome 3) and rs1053865678 (chromosome 5)(16). We repeated this

analysis for the 1,050 UK Biobank participants with APOL1 protein concentration data within our previously-defined recent sub-Saharan African ancestry cohort. Age, sex, and the first four principal components were taken as covariates. Our GWAS confirmed the association with APOL1 G2 ( $p = 3 \times 10^{-155}$ ), however no association with rs138477541 or rs1053865678 was detected. A SNP at a separate location on chromosome 3, rs112693005 (no previous associations reported), almost reached genome-wide significance ( $p = 6 \times 10^{-8}$ ), however we did not detect genome-wide significance ( $p < 5 \times 10^{-8}$ ) on any other chromosomes. The genome-wide scan failed to identify genetic factors or covariates that would explain the elevated APOL1 concentration among sub-Saharan Africans.

## Discussion

Recent laboratory and association studies have transformed our understanding of the human *APOL1* gene: widening the scope of potentially detrimental effects in current populations as an evolutionary cost of surviving historic sleeping sickness epidemics (8,13,20–22) as well as identifying an additional modifying variant that mitigates APOL1 impact both on trypanosomiasis and CKD(9–12), and demonstrating significant phenotypic differences between the G1 and G2 variants(8). In studies examining the role of APOL1 in trypanosomiasis, these differences are well-established: G1 is protective against severe disease in *T.b. gambiense*; G2 prevents *T.b. rhodesiense* infection, but is associated with increased disease severity in *T.b. gambiense* (3), and the two variants are considered separately, with distinct phenotypes. Despite this, studies of *APOL1*'s role in other conditions such as CKD have typically considered G1 and G2 as equivalent, grouping genotypes G1/G1, G1/G2, and G2/G2 together as collectively 'high-risk'. Recently, we demonstrated that this approach masks a deeper level of complexity, and identified conditions and phenotypes within CKD that were associated with particular two-variant *APOL1* genotypes(8). Here we show that these differences extend to APOL1 serum protein concentration, and also provide further evidence that the APOL1 N264K variant modifies the G2 protein concentration phenotype.

Our data indicates that APOL1 G1 and G2 are both associated with increased APOL1 serum protein concentration, however the effect of G2 is far larger and dose-dependent. Previous studies have demonstrated G2-specific phenotypes in human African trypanosomiasis and CKD. In *T.b. rhodesiense* infection, a parasite serum resistance-associated (SRA) protein binds and blocks APOL1-mediated trypanolysis, permitting human infection. However the two amino acid deletion present in the G2 variant modifies APOL1 to prevent SRA binding, thus restoring APOL1 lytic function and protecting against trypanosome infection(23). The G2/G2 genotype has also been associated with reduced ( $< 60 \text{ mL/min/1.73m}^2$ ) estimated glomerular filtration rate(8): an indicator of CKD. The mechanisms resulting in APOL1-mediated cell injury in CKD are unclear: multiple pathways have been proposed, and studies have typically examined genotypes G1/G1, G1/G2, and G2/G2 collectively as 'high-risk'. The molecular pathways underpinning CKD phenotypes might be specific to individual *APOL1* genotypes.

Phenome-wide screening of *APOL1* G1 and G2 genotypes revealed multiple deleterious associations specifically with the G1/G2 genotype (8), however the analysis did not detect any *International Classification of Disease* (ICD) codes associated with G2/G2 (either

protective or deleterious). Given the substantial increase in APOL1 protein concentration in G2/G2, this is surprising. The lack of associations may be due to reduced statistical power (G2/G2 is the least common of the six observed *APOL1* genotypes, and the genome-wide screen included only 153 G2/G2 participants compared to 320 who were G1/G2) or there might be additional, as yet undetected modifiers that mask the effects of G2 homozygosity. Alternatively, the presence of APOL1 G2 protein at increased concentration might not impact on ICD phenotypes.

The APOL1 N264K variant in a G2 background has previously been associated with reduced trypanolytic function (9). Subsequently, N264K has been shown to be associated with a protective effect against G2-associated kidney disease, interrupting APOL1 G2 pore-forming function and ion channel conduction(11,12). Here, we demonstrate that in the presence of G2, the N264K variant also reduces protein concentration. Although genotypes containing G2 and N264K have higher APOL1 protein concentration than G0/G0, the protein concentration reduction and pore disruption actions of N264K might be sufficient to reduce the severity of the phenotype. N264K may also have additional, as yet unidentified, phenotype-modifying actions. The presence, simultaneously of N264K and G2 in an individual has potential clinical implications: the G2 carriers who do not carry the N264K variant are potentially at highest risk of developing kidney disease, and perhaps require more frequent monitoring of their condition.

The data presented here demonstrates the association between *APOL1* variants and protein concentration, however the elevated protein concentration among individuals with the G0/G0 genotype who have sub-Saharan African ancestry (relative to those of non-sub-Saharan African ancestry) indicates that APOL1 protein concentration is influenced by additional factors. The difference might be attributable to many loci of small effect as well as environmental factors that were not incorporated into our model. The identification of additional loci and environmental factors that influence APOL1 protein concentration, and an assessment of their impact on human health would further develop our understanding of the protein and inform diagnostics and management for *APOL1*-related conditions.

## Conclusions

This study demonstrates the relationship between *APOL1* variants and APOL1 protein concentration. It identifies further phenotypic differences between the G1 and G2 variants, highlighting the value in considering them as distinct in molecular and association studies. Furthermore, it provides further detail on the relationship between the G2 and N264K variants, which has significant implications for diagnosis and therapy in kidney disease.

## Data sharing statement

This research has been conducted using data from the UK Biobank, a major biomedical database: [www.ukbiobank.ac.uk](http://www.ukbiobank.ac.uk).

## Acknowledgements

We thank NHS England (Copyright 2023, NHS England. Re-used with the permission of the NHS England. All rights reserved. This work uses data provided by patients and collected by the NHS as part of their care and support).

We thank Public Health Scotland. (This research used data assets made available by National Safe Haven as part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation).

This study was funded by the Wellcome Trust (209511/Z/17/Z) and H3Africa (H3A/18/004).

## References

1. Yusuf AA, Govender MA, Brandenburg JT, Winkler CA. Kidney disease and APOL1. *Hum Mol Genet.* 2021 Apr 26;30(R1):R129–37.
2. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, et al. Association of Trypanolytic ApoL1 Variants with Kidney Disease in African Americans. *Science.* 2010 Aug 13;329(5993):841–5.
3. Cooper A, Ilboudo H, Alibu VP, Ravel S, Enyaru J, Weir W, et al. APOL1 renal risk variants have contrasting resistance and susceptibility associations with African trypanosomiasis. *eLife.* 2017 May 24;6:e25461.
4. Capewell P, Cooper A, Clucas C, Weir W, Macleod A. A co-evolutionary arms race: trypanosomes shaping the human genome, humans shaping the trypanosome genome. *Parasitology.* 2015 Feb;142(S1):S108–19.
5. Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. *J Am Soc Nephrol JASN.* 2011 Nov;22(11):2129–37.
6. Kasembeli AN, Duarte R, Ramsay M, Mosiane P, Dickens C, Dix-Peek T, et al. *APOL1* Risk Variants Are Strongly Associated with HIV-Associated Nephropathy in Black South Africans. *J Am Soc Nephrol.* 2015 Nov;26(11):2882–90.
7. Beckerman P, Susztak K. APOL1: The Balance Imposed by Infection, Selection, and Kidney Disease. *Trends Mol Med.* 2018 Aug;24(8):682–95.
8. Adamson WE, Noyes H, Johnson P, Cooper A, Monckton DG, Ogunsola J, et al. Phenome-wide analysis reveals epistatic associations between APOL1 variants and chronic kidney disease and multiple other disorders. *eBioMedicine.* 2024 Feb;105000.
9. Cuypers B, Lecordier L, Meehan CJ, Van den Broeck F, Imamura H, Büscher P, et al. Apolipoprotein L1 Variant Associated with Increased Susceptibility to Trypanosome Infection. *mBio.* 2016 Apr 12;7(2):e02198-02115.

10. Lannon H, Shah SS, Dias L, Blackler D, Alper SL, Pollak MR, et al. Apolipoprotein L1 (APOL1) risk variant toxicity depends on the haplotype background. *Kidney Int.* 2019 Dec;96(6):1303–7.
11. Hung AM, Assimon VA, Chen HC, Yu Z, Vlasschaert C, Triozi JL, et al. Genetic Inhibition of APOL1 Pore-Forming Function Prevents APOL1-Mediated Kidney Disease. *J Am Soc Nephrol.* 2023 Nov;34(11):1889–99.
12. Gupta Y, Friedman DJ, McNulty MT, Khan A, Lane B, Wang C, et al. Strong protective effect of the APOL1 p.N264K variant against G2-associated focal segmental glomerulosclerosis and kidney disease. *Nat Commun.* 2023 Nov 30;14(1):7836.
13. Wu J, Ma Z, Raman A, Beckerman P, Dhillon P, Mukhi D, et al. APOL1 risk variants in individuals of African genetic ancestry drive endothelial cell defects that exacerbate sepsis. *Immunity.* 2021 Nov;54(11):2632–2649.e6.
14. Kozlitina J, Zhou H, Brown PN, Rohm RJ, Pan Y, Ayanoglu G, et al. Plasma Levels of Risk-Variant APOL1 Do Not Associate with Renal Disease in a Population-Based Cohort. *J Am Soc Nephrol.* 2016 Oct;27(10):3204–19.
15. Sun BB, Chiou J, Traylor M, Benner C, Hsu YH, Richardson TG, et al. Plasma proteomic associations with genetics and health in the UK Biobank. *Nature.* 2023 Oct 12;622(7982):329–38.
16. Eldjarn GH, Ferkingstad E, Lund SH, Helgason H, Magnusson OTh, Gunnarsdottir K, et al. Large-scale plasma proteomics comparisons through genetics and disease associations. *Nature.* 2023 Oct 12;622(7982):348–58.
17. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature.* 2018 Oct;562(7726):203–9.
18. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. *GigaScience.* 2015 Dec;4(1):7.
19. Mbatchou J, Barnard L, Backman J, Marcketta A, Kosmicki JA, Ziyatdinov A, et al. Computationally efficient whole-genome regression for quantitative and binary traits. *Nat Genet.* 2021 Jul;53(7):1097–103.
20. Velez JCQ, Caza T, Larsen CP. COVAN is the new HIVAN: the re-emergence of collapsing glomerulopathy with COVID-19. *Nat Rev Nephrol.* 2020 Oct;16(10):565–7.
21. Larsen CP, Wickman TJ, Braga JR, Matute-Trochez LA, Hasty AE, Buckner LR, et al. *APOL1* Risk Variants and Acute Kidney Injury in Black Americans with COVID-19. *Clin J Am Soc Nephrol.* 2021 Dec;16(12):1790–6.
22. Hung AM, Shah SC, Bick AG, Yu Z, Chen HC, Hunt CM, et al. *APOL1* Risk Variants, Acute Kidney Injury, and Death in Participants With African Ancestry Hospitalized With COVID-19 From the Million Veteran Program. *JAMA Intern Med.* 2022 Apr 1;182(4):386.

23. Thomson R, Genovese G, Canon C, Kovacsics D, Higgins MK, Carrington M, et al. Evolution of the primate trypanolytic factor APOL1. Proc Natl Acad Sci [Internet]. 2014 May 20 [cited 2024 Jan 19];111(20). Available from: <https://pnas.org/doi/full/10.1073/pnas.1400699111>